These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18030011)

  • 1. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
    Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
    Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
    Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
    Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term amrubicin chemotherapy for small-cell lung cancer.
    Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Kawase I
    Anticancer Res; 2012 Apr; 32(4):1423-7. PubMed ID: 22493380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
    Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
    Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
    Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
    Suzuki H; Sasada S; Matsuda Y; Otani Y; Morishita N; Kobayashi M; Okamoto N; Hirashima T; Matsui K; Kawase I
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):491-3. PubMed ID: 18347402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
    Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
    Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
    Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H
    Invest New Drugs; 2007 Aug; 25(4):377-83. PubMed ID: 17351748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal.
    Mallik S; Palaian S; Ojha P; Mishra P
    Pak J Pharm Sci; 2007 Jul; 20(3):214-8. PubMed ID: 17545106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.